Attribution of Value Framework for Combination Therapies

This report presents the findings of the Value Attribution Working Group regarding the Attribution of Value Framework for combination therapies. It discusses the challenges in evaluating combination treatments, particularly how they are assessed as single technologies despite being composed of multiple independently priced components. The report outlines the historical context, including a 2014 paper by the UK National Institute of Health and Care Excellence (NICE) that highlighted the cost-effectiveness issues surrounding combination therapies. It details the outcomes of a workshop convened by the Bellberry Group in 2019, which brought together various stakeholders to address valuation and payment challenges in oncology. The report proposes a framework for attributing value to the components of combination treatments and suggests a standard operating procedure for arbitration processes considering competition law. Additionally, it emphasizes the need for dedicated research on value attribution methods and aims to facilitate further discussion among stakeholders to ensure patient access to effective treatments.